Bristol Myers Squibb (BMY)

Total Costs & Expenses

$35.35B

TTM · Period ending: · USD

BMY logo

BMY Total Costs & Expenses

Latest reported$35.35B
BMY TTM Total Costs & Expenses ($6.09B → $35.35B)
High-resolution chart · PNG

BMY total costs & expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Bristol Myers Squibb Total Costs & Expenses — Trailing twelve months (TTM) (USD)
Period endingTotal Costs & Expenses (USD)
35,345,000,000
34,892,000,000
34,472,000,000
36,614,000,000
37,751,000,000
39,766,000,000
42,413,000,000
40,155,000,000
39,442,000,000
38,257,000,000
36,811,000,000
36,949,000,000
37,061,000,000
36,981,000,000
37,055,000,000
37,077,000,000
37,563,000,000
37,677,000,000
37,937,000,000
40,110,000,000
39,703,000,000
39,582,000,000
40,341,000,000
35,822,000,000
30,872,000,000
26,031,000,000
20,235,000,000
17,253,000,000
17,037,000,000
17,831,000,000
17,443,000,000
18,001,000,000
18,272,000,000
17,516,000,000
17,355,000,000
16,660,000,000
15,963,000,000
15,263,000,000
14,888,000,000
15,037,000,000
14,884,000,000
15,189,000,000
14,830,000,000
14,671,000,000
14,436,000,000
13,986,000,000
14,165,000,000
13,485,000,000
13,546,000,000
13,376,000,000
13,454,000,000
13,545,000,000
13,445,000,000
13,460,000,000
13,692,000,000
13,898,000,000
14,323,000,000
14,585,000,000
14,597,000,000
14,697,000,000
14,320,000,000
13,879,000,000
13,787,000,000
11,945,000,000
12,064,000,000
12,092,000,000
12,090,000,000
14,388,000,000
15,080,000,000
15,714,000,000
16,193,000,000
16,037,000,000
15,722,000,000
15,424,000,000
15,151,000,000
14,872,000,000
14,845,000,000
15,066,000,000
15,293,000,000
15,479,000,000
15,570,000,000
15,494,000,000
15,256,000,000
13,430,000,000
13,249,000,000
13,156,000,000
13,117,000,000
15,379,000,000
15,750,000,000
15,955,000,000
16,072,000,000
15,365,000,000
14,850,000,000
14,248,000,000
13,824,000,000
13,727,000,000
13,253,000,000
13,210,000,000
13,114,000,000
12,477,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.